FLICE-like inhibitory protein blocks transforming growth factor β1-induced caspase activation and apoptosis in prostate epithelial cells

Molecular Cancer Research

Volumn 6, Issue 2, 2008, Pages 231-242

  Nastiuk, Kent L ^a   Yoo, Kiwon ^a   Lo, Karen ^a   Su, Kevin ^a   Yeung, Patricia ^a   Kutaka, Julia ^a   Danielpour, David ^c   Krolewski, John J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CASPASE 3; CASPASE 8; DEATH RECEPTOR 5; FAS ANTIGEN; FLICE INHIBITORY PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; INSULIN; MITOGENIC AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2;

ANIMAL CELL; APOPTOSIS; ARTICLE; CASTRATION; CELL DEATH; CELL DIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC TRANSFECTION; HORMONAL REGULATION; MALE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; RAT;

ANIMALS; APOPTOSIS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASES; CELL DIFFERENTIATION; CELL LINE; CELL SURVIVAL; ENZYME ACTIVATION; EPITHELIAL CELLS; FAS LIGAND PROTEIN; GENE EXPRESSION REGULATION; HUMANS; IMMUNOGLOBULIN G; INSULIN; MALE; MICE; PROSTATE; RATS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; RNA, MESSENGER; SOLUBILITY; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA1;

RATTUS;

EID: 40349103658     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-07-0386     Document Type: Article

References (67)

1. Isaacs JT. Antagonistic effect of androgen on prostatic cell death. Prostate 1984;5:545-57.
2. Nastiuk KL, Kim JW, Mann M, Krolewski JJ. Androgen regulation of FLICE-like inhibitory protein gene expression in the rat prostate. J Cell Physiol 2003;196:386-93.
3. Colombel MC, Buttyan R. Hormonal control of apoptosis: the rat prostate gland as a model system. Methods Cell Biol 1995;46:369-85.
4. Brodin G, ten Dijke P, Funa K, Heldin CH, Landstrom M. Increased smad expression and activation are associated with apoptosis in normal and malignant prostate after castration. Cancer Res 1999;59:2731-8.
5. Kyprianou N, Isaacs JT. Expression of transforming growth factor-β in the rat ventral prostate during castration-induced programmed cell death. Mol Endocrinol 1989;3:1515-22.
6. Kim IY, Ahn HJ, Zelner DJ, et al. Expression and localization of transforming growth factor-β receptors type I, type II, in the rat ventral prostate during regression. Mol Endocrinol 1996;10:107-15.
7. Kundu SD, Kim IY, Yang T, et al. Absence of proximal duct apoptosis in the ventral prostate of transgenic mice carrying the C3(1)-TGF-β type II dominant negative receptor. Prostate 2000;43:118-24.
8. Tang B, de Castro K, Barnes HE, et al. Loss of responsiveness to transforming growth factor β induces malignant transformation of nontumorigenic rat prostate epithelial cells. Cancer Res 1999;59:4834-42.
9. Martikainen P, Kyprianou N, Isaacs JT. Effect of transforming growth factor-β1 on proliferation and death of rat prostatic cells. Endocrinology 1990;127:2963-8.
10. Coyle B, Freathy C, Gant TW, Roberts RA, Cain K. Characterization of the transforming growth factor-β1-induced apoptotic transcriptome in FaO hepatoma cells. J Biol Chem 2003;278:5920-8.
11. Nagata S. Apoptosis by death factor. Cell 1997;88:355-65.
12. Nagata S, Golstein P. The FAS death factor. Science 1995;267:1449-56.
13. Gao S, Wang H, Lee P, et al. Androgen receptor and prostate apoptosis response factor-4 target the c-FLIP gene to determine survival and apoptosis in the prostate gland. J Mol Endocrinol 2006;36:463-83.
14. Gao S, Lee P, Wang H, et al. The androgen receptor directly targets the cellular Fas/FasL-associated death domain protein-like inhibitory protein gene to promote the androgen-independent growth of prostate cancer cells. Mol Endocrinol 2005;19:1792-802.
15. Peter ME, Krammer PH. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 2003;10:26-35.
16. Xerri L, Devilard E, Hassoun J, Mawas C, Birg F. Fas ligand is not only expressed in immune privileged human organs but is also coexpressed with Fas in various epithelial tissues. Mol Pathol 1997;50:87-91.
17. Sasaki Y, Ahmed H, Takeuchi T, Moriyama N, Kawabe K. Immunohistochemical study of Fas, Fas ligand and interleukin-1β converting enzyme expression in human prostatic cancer. Br J Urol 1998;81:852-5.
18. Nesterov A, Ivashchenko Y, Kraft AS. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers apoptosis in normal prostate epithelial cells. Oncogene 2002;21:1135-40.
19. Yu R, Mandlekar S, Ruben S, Ni J, Kong AN. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in androgen-independent prostate cancer cells. Cancer Res 2000;60:2384-9.
20. Voelkel-Johnson C, King DL, Norris JS. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Cancer Gene Ther 2002;9:164-72.
21. Bin L, Li X, Xu LG, Shu HB. The short splice form of Casper/c-FLIP is a major cellular inhibitor of TRAIL-induced apoptosis. FEBS Lett 2002;510:37-40.
22. MacFarlane M. TRAIL-induced signalling and apoptosis. Toxicol Lett 2003;139:89-97.
23. Kelly MM, Hoel BD, Voelkel-Johnson C. Doxorubicin pretreatment sensitizes prostate cancer cell lines to TRAIL induced apoptosis which correlates with the loss of c-FLIP expression. Cancer Biol Ther 2002;1:520-7.
24. Siegmund D, Hadwiger P, Pfizenmaier K, Vornlocher HP, Wajant H. Selective inhibition of FLICE-like inhibitory protein expression with small interfering RNA oligonucleotides is sufficient to sensitize tumor cells for TRAIL-induced apoptosis. Mol Med 2002;8:725-32.
25. Zhang X, Jin TG, Yang H, et al. Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer. Cancer Res 2004;64:7086-91.
26. Rippo MR, Moretti S, Vescovi S, et al. FLIP overexpression inhibits death receptor-induced apoptosis in malignant mesothelial cells. Oncogene 2004;23:7753-60.
27. Abedini MR, Qiu Q, Yan X, Tsang BK. Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro. Oncogene 2004;23:6997-7004.
28. Kimura K, Bowen C, Spiegel S, Gelmann EP. Tumor necrosis factor-α sensitizes prostate cancer cells to gamma-irradiation-induced apoptosis. Cancer Res 1999;59:1606-14.
29. Kramer G, Steiner GE, Sokol P, et al. Local intratumoral tumor necrosis factor-α and systemic IFN-α2b in patients with locally advanced prostate cancer. J Interferon Cytokine Res 2001;21:475-84.
30. Frost PJ, Belldegrun A, Bonavida B. Sensitization of immunoresistant prostate carcinoma cell lines to Fas/Fas ligand-mediated killing by cytotoxic lymphocytes: independence of de novo protein synthesis. Prostate 1999;41:20-30.
31. Danielpour D, Kadomatsu K, Anzano MA, Smith JM, Sporn MB. Development and characterization of nontumorigenic and tumorigenic epithelial cell lines from rat dorsal-lateral prostate. Cancer Res 1994;54:3413-21.
32. Danielpour D. Transdifferentiation of NRP-152 rat prostatic basal epithelial cells toward a luminal phenotype: regulation by glucocorticoid, insulin-like growth factor-I and transforming growth factor-β. J Cell Sci 1999;112:169-79.
33. Hsing AY, Kadomatsu K, Bonham MJ, Danielpour D. Regulation of apoptosis induced by transforming growth factor-β1 in nontumorigenic rat prostatic epithelial cell lines. Cancer Res 1996;56:5146-9.
34. Song K, Cornelius SC, Reiss M, Danielpour D. Insulin-like growth factor-I inhibits transcriptional responses of transforming growth factor-β by phosphatidylinositol 3-kinase/Akt-dependent suppression of the activation of Smad3 but not Smad2. J Biol Chem 2003;278:38342-51.
35. Goltsev YV, Kovalenko AV, Arnold E, et al. CASH, a novel caspase homologue with death effector domains. J Biol Chem 1997;272:19641-4.
36. Shu HB, Halpin DR, Goeddel DV. Casper is a FADD- and caspase-related inducer of apoptosis. Immunity 1997;6:751-63.
37. Inohara N, Koseki T, Hu Y, Chen S, Nunez G. CLARP, a death effector domain-containing protein interacts with caspase-8 and regulates apoptosis. Proc Natl Acad Sci U S A 1997;94:10717-22.
38. Peter ME. The flip side of FLIP. Biochem J 2004;382:e1-3.
39. Micheau O, Thome M, Schneider P, et al. The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. J Biol Chem 2002;277:45162-71.
40. Hedlund TE, Duke RC, Schleicher MS, Miller GJ. Fas-mediated apoptosis in seven human prostate cancer cell lines: correlation with tumor stage. Prostate 1998;36:92-101.
41. Hedlund TE, Meech SJ, Srikanth S, et al. Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells. Cell Death Differ 1999;6:175-82.
42. Rokhlin OW, Bishop GA, Hostager BS, et al. Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res 1997;57:1758-68.
43. Rokhlin OW, Guseva NV, Tagiyev AF, Glover RA, Cohen MB. Caspase-8 activation is necessary but not sufficient for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in the prostatic carcinoma cell line LNCaP. Prostate 2002;52:1-11.
44. Truneh A, Sharma S, Silverman C, et al. Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J Biol Chem 2000;275:23319-25.
45. Schneider P, Olson D, Tardivel A, et al. Identification of a new murine tumor necrosis factor receptor locus that contains two novel murine receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Biol Chem 2003;278:5444-54.
46. Wallace CS, Withers GS, Weiler IJ, et al. Correspondence between sites of NGFI-A induction and sites of morphological plasticity following exposure to environmental complexity. Brain Res Mol Brain Res 1995;32:211-20.
47. Vindrieux D, Devonec M, Benahmed M, Grataroli R. Identification of tumor necrosis factor-α-related apoptosis-inducing ligand (TRAIL) and its receptors in adult rat ventral prostate. Mol Cell Endocrinol 2002;198:115-21.
48. Munshi A, Pappas G, Honda T, et al. TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2. Oncogene 2001;20:3757-65.
49. Sridhar S, Ali AA, Liang Y, et al. Differential expression of members of the tumor necrosis factor α-related apoptosis-inducing ligand pathway in prostate cancer cells. Cancer Res 2001;61:7179-83.
50. Herzer K, Ganten TM, Schulze-Bergkamen H, et al. Transforming growth factor β can mediate apoptosis via the expression of TRAIL in human hepatoma cells. Hepatology 2005;42:183-92.
51. Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003;114:181-90.
52. Chang L, Kamata H, Solinas G, et al. The E3 ubiquitin ligase itch couples JNK activation to TNFα-induced cell death by inducing c-FLIP(L) turnover. Cell 2006;124:601-13.
53. Chopra DP, Menard RE, Januszewski J, Mattingly RR. TNF-α-mediated apoptosis in normal human prostate epithelial cells and tumor cell lines. Cancer Lett 2004;203:145-54.
54. Mukhopadhyay A, Bueso-Ramos C, Chatterjee D, Pantazis P, Aggarwal BB. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 2001;20:7597-609.
55. Grounds MD, Davies M, Torrisi J, et al. Silencing TNFα activity by using Remicade or Enbrel blocks inflammation in whole muscle grafts: an in vivo bioassay to assess the efficacy of anti-cytokine drugs in mice. Cell Tissue Res 2005;320:509-15.
56. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002;2:420-30.
57. Wiley SR, Winkles JA. TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine Growth Factor Rev 2003;14:241-9.
58. Kim SG, Jong HS, Kim TY, et al. Transforming growth factor-β 1induces apoptosis through Fas ligand-independent activation of the Fas death pathway in human gastric SNU-620 carcinoma cells. Mol Biol Cell 2004;15:420-34.
59. Song K, Wang H, Krebs TL, Danielpour D. Novel roles of Akt and mTOR in suppressing TGF-β/ALK5-mediated Smad3 activation. EMBO J 2006;25:58-69.
60. Wanke I, Schwarz M, Buchmann A. Insulin and dexamethasone inhibit TGF-β-induced apoptosis of hepatoma cells upstream of the caspase activation cascade. Toxicol 2004;204:141-54.
61. Ghosh PM, Malik SN, Bedolla RG, et al. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation. Endocr Relat Cancer 2005;12:119-34.
62. Ren M, Guan Q, Zhong X, et al. Phosphatidylinositol 3-kinase/nuclear factor-κB signaling pathway is involved in the regulation of IGF-I on Fas-associated death domain-like interleukin-1-converting enzyme-inhibitory protein expression in cultured FRTL thyroid cells. J Mol Endocrinol 2007;38:619-25.
63. Monti S, Proietti-Pannunzi L, Sciarra A, et al. The IGF axis in prostate cancer. Curr Pharm Des 2007;13:719-27.
64. Chipuk JE, Bhat M, Hsing AY, Ma J, Danielpour D. Bcl-xL blocks transforming growth factor-β1-induced apoptosis by inhibiting cytochrome c release and not by directly antagonizing Apaf-1-dependent caspase activation in prostate epithelial cells. J Biol Chem 2001;276:26614-21.
65. Tilly JL, Hsueh AJW. Microscale autoradiographic method for the qualitative and quantitative analysis of apoptotic DNA fragmentation. J Cell Physiol 1993;154:519-26.
66. Zettlmeissl G, Gregersen JP, Duport JM, et al. Expression and characterization of human CD4:immunoglobulin fusion proteins. DNA Cell Biol 1990;9:347-53.
67. Morrison TB, Weis JJ, Wittwer CT. Quantification of low-copy transcripts by continuous SYBR® Green I monitoring during amplification. BioTechniques 1998;24:954-62.